Zacks: Analysts Anticipate Radius Health Inc (NASDAQ:RDUS) Will Post Earnings of -$0.80 Per Share

Wall Street brokerages forecast that Radius Health Inc (NASDAQ:RDUS) will announce earnings per share of ($0.80) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Radius Health’s earnings. The highest EPS estimate is ($0.69) and the lowest is ($0.91). Radius Health reported earnings per share of ($0.85) during the same quarter last year, which indicates a positive year over year growth rate of 5.9%. The company is scheduled to report its next earnings report on Thursday, November 7th.

On average, analysts expect that Radius Health will report full-year earnings of ($3.25) per share for the current year, with EPS estimates ranging from ($3.58) to ($2.98). For the next financial year, analysts expect that the firm will report earnings of ($2.67) per share, with EPS estimates ranging from ($3.51) to ($1.75). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Radius Health.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.77) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.09. Radius Health had a negative net margin of 127.22% and a negative return on equity of 368.58%. The business had revenue of $41.04 million during the quarter, compared to analyst estimates of $40.60 million. During the same period last year, the business posted ($0.99) earnings per share. Radius Health’s quarterly revenue was up 81.4% compared to the same quarter last year.

Several equities analysts have recently issued reports on RDUS shares. Morgan Stanley started coverage on shares of Radius Health in a report on Thursday, September 5th. They set a “buy” rating and a $43.00 target price for the company. Citigroup upgraded shares of Radius Health from a “neutral” rating to a “buy” rating and lifted their target price for the company from $24.00 to $40.00 in a report on Thursday, August 29th. Cowen reiterated a “hold” rating on shares of Radius Health in a report on Thursday, August 8th. BidaskClub upgraded shares of Radius Health from a “hold” rating to a “buy” rating in a report on Friday, October 18th. Finally, ValuEngine lowered shares of Radius Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. Radius Health has a consensus rating of “Buy” and an average price target of $36.50.

A number of hedge funds and other institutional investors have recently made changes to their positions in RDUS. Price T Rowe Associates Inc. MD raised its holdings in Radius Health by 51.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,875,313 shares of the biopharmaceutical company’s stock worth $94,403,000 after acquiring an additional 1,314,899 shares during the last quarter. Emerald Advisers LLC raised its holdings in Radius Health by 596.4% in the 2nd quarter. Emerald Advisers LLC now owns 662,113 shares of the biopharmaceutical company’s stock worth $16,129,000 after acquiring an additional 567,038 shares during the last quarter. Nuveen Asset Management LLC purchased a new position in Radius Health in the 2nd quarter worth approximately $13,766,000. Emerald Mutual Fund Advisers Trust raised its holdings in Radius Health by 582.1% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 611,767 shares of the biopharmaceutical company’s stock worth $14,903,000 after acquiring an additional 522,077 shares during the last quarter. Finally, Great Lakes Advisors LLC purchased a new position in Radius Health in the 2nd quarter worth approximately $7,743,000.

RDUS traded down $0.08 on Thursday, hitting $27.25. The company had a trading volume of 494,600 shares, compared to its average volume of 557,764. The stock has a fifty day simple moving average of $26.83 and a 200-day simple moving average of $23.58. Radius Health has a 52-week low of $12.81 and a 52-week high of $29.97. The firm has a market capitalization of $1.25 billion, a P/E ratio of -5.58 and a beta of 0.78. The company has a debt-to-equity ratio of 6.75, a current ratio of 4.38 and a quick ratio of 4.28.

About Radius Health

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: What are the disadvantages of after-hours trading?

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.